Yipinhong (300723.SZ): Two products are expected to win bids in the twelfth batch of national centralized drug procurement.

According to the information from the Zhitong Finance APP, Yipinhong (300723.SZ) announced that on July 31, 2026, its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. (hereinafter referred to as "Yipinhong Pharmaceutical") and Guangzhou Lianrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Lianrui Pharmaceutical") participated in the bidding work for the twelfth batch of national centralized drug procurement organized by the National Organization of Drug Joint Procurement Office. Yipinhong Pharmaceutical intends to bid for the injectable isavuconazole that has passed the quality and efficacy consistency evaluation for generic drugs, and Lianrui Pharmaceutical intends to bid for perindopril and amlodipine tablets (III) that has also passed the quality and efficacy consistency evaluation for generic drugs in this centralized procurement.